Publicaciones en las que colabora con Fernando Lecanda Cordero (27)

2024

  1. Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma

    Cancer Epidemiology, Vol. 92

2022

  1. Genomic and proteomic profiling of osteosarcoma

    Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to Bedside (Elsevier), pp. 591-604

2020

  1. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients with Osteosarcoma

    JAMA Oncology, Vol. 6, Núm. 5, pp. 724-734

  2. Sarcoma treatment in the era of molecular medicine

    EMBO Molecular Medicine, Vol. 12, Núm. 11

  3. Wnt signaling and Loxl2 promote aggressive osteosarcoma

    Cell Research, Vol. 30, Núm. 10, pp. 885-901

2019

  1. CYR61 triggers osteosarcoma metastatic spreading via an IGF1Rβ-dependent EMT-like process

    BMC Cancer, Vol. 19, Núm. 1

2018

  1. Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients

    International Journal of Cancer, Vol. 142, Núm. 8, pp. 1594-1601

2016

  1. Erratum: Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1 (Oncogene (2016) 35 (2852-2861) DOI:10.1038/onc.2015.344)

    Oncogene

  2. Matrix-Gla protein promotes osteosarcoma lung metastasis and associates with poor prognosis

    Journal of Pathology, Vol. 239, Núm. 4, pp. 438-449

  3. Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1

    Oncogene, Vol. 35, Núm. 22, pp. 2852-2861

2015

  1. A genome-wide scan identifies variants in NFIB associated with metastasis in patients with osteosarcoma

    Cancer Discovery, Vol. 5, Núm. 9, pp. 920-931

  2. Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types

    Journal of the National Cancer Institute, Vol. 107, Núm. 12

  3. Gene and proteomic profiling of osteosarcoma

    Bone Cancer: Primary Bone Cancers and Bone Metastases: Second Edition (Elsevier Inc.), pp. 223-234

  4. Germline TP53 Variants and Susceptibility to Osteosarcoma

    Journal of the National Cancer Institute, Vol. 107, Núm. 7

2014

  1. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33

    Human Molecular Genetics, Vol. 23, Núm. 24, pp. 6616-6633

  2. The oncolytic adenovirus Δ24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity

    Journal of Bone and Mineral Research, Vol. 29, Núm. 10, pp. 2287-2296

2013

  1. ErbB3 silencing reduces osteosarcoma cell proliferation and tumor growth in vivo

    Gene, Vol. 521, Núm. 1, pp. 55-61

  2. FHL2 Silencing Reduces Wnt Signaling and Osteosarcoma Tumorigenesis In Vitro and In Vivo

    PLoS ONE, Vol. 8, Núm. 1

  3. Genome-wide association study identifies two susceptibility loci for osteosarcoma

    Nature Genetics, Vol. 45, Núm. 7, pp. 799-803

  4. Zinc chelation: A metallothionein 2A's mechanism of action involved in osteosarcoma cell death and chemotherapy resistance

    Cell Death and Disease, Vol. 4, Núm. 10